We are an early stage pharmaceutical development company focused on the development of menaquinone-7 for the treatment of vascular and other tissue calcification-related diseases.
Our Mission
To develop a novel and potentially groundbreaking therapy to help patients prevent and reverse vascular calcification.
About Us
Kaydence Pharma is an emerging pharmaceutical company focused exclusively on the development of menaquinone-7 as a pharmaceutical product for vascular and other tissue calcification-related diseases.
Our Journey
Calcification-induced vascular stiffening is now recognized as an important predictor of cardiovascular disease and a major risk factor across multiple conditions, including chronic kidney disease, aortic stenosis, and arteriosclerosis…